Results 111 to 120 of about 38,575 (293)

Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis [PDF]

, 2016
Genome-wide association studies (GWAS) have revealed genetic determinants of iron metabolism, but correlation of these with clinical phenotypes is pending.
Aigner, Elmar, Arlt, Alexander, Becker, Thomas, Berg, Thomas, Boehm, Bernhard O., Braun, Felix, Buch, Stephan, D'Amato, Mauro, Datz, Christian, Dejaco, Christian, Erhart, Wiebke, Finkenstedt, Armin, Franke, Andre, Gallati, Sabina, Hampe, Jochen, Hinrichsen, Holger, Hultcrantz, Rolf, Kratzer, Wolfgang, Krawczak, Michael, Krones, Elisabeth, Lerch, Markus M., Mayerle, Julia, Nothnagel, Michael, Sahinbegovic, Enijad, Sarrazin, Christoph, Schafmayer, Clemens, Schaller, André, Sipos, Bence, Stadlmayr, Andreas, Stal, Per, Stickel, Felix, Strasser, Michael, Torkvist, Leif, Völzke, Henry, Zoller, Heinz, Zwerina, Jochen, Österreicher, Christoph   +36 more
core   +2 more sources

A New Case of PCSK1 Pathogenic Variant With Congenital Proprotein Convertase 1/3 Deficiency and Literature Review

Journal of Clinical Endocrinology and Metabolism, 2018
Issue To report a homozygous pathogenic variant in PCSK1 in a boy affected with proprotein convertase 1/3 (PC1/3) deficiency. Case Description and Literature Review A male infant born to consanguineous Turkish parents presented in the first week of ...
L. Pépin, E. Colin, Marine Tessarech, S. Rouleau, N. Bouhours-Nouet, D. Bonneau, R. Coutant   +6 more
semanticscholar   +1 more source

Proprotein Convertase Inhibition Results in Decreased Ski Proliferation, Tumorigenesis, and Metastasis

Neoplasia: An International Journal for Oncology Research, 2010
PACE4 is a proprotein convertase (PC) responsible for cleaving and activating proteins that contribute to enhance tumor progression. PACE4 overexpression significantly increased the susceptibility to carcinogenesis, leading to enhanced tumor cell ...
Daniel E. Bassi, Jirong Zhang, Jonathan Cenna, Samuel Litwin, Edna Cukierman, Andres J.P. Klein-Szanto   +5 more
doaj   +1 more source

Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents [PDF]

, 2011
Background During the past decade, proprotein convertase subtilisin kexin type 9 (PCSK9) has been identified as a key regulator of serum LDL-cholesterol (LDL-C) levels.
Cao, Guoqing, Konrad, Robert J, Troutt, Jason S   +2 more
core   +3 more sources

Correction to: PCSK9 (Proprotein Convertase Subtilisin/Kexin 9) Enhances Platelet Activation, Thrombosis, and Myocardial Infarct Expansion by Binding to Platelet CD36.

Circulation, 2021

semanticscholar   +1 more source

Long-term exposure to air pollution raises circulating levels of proprotein convertase subtilisin/kexin type 9 in obese individuals

European Journal of Preventive Cardiology, 2018
Aims Exposure to airborne particulate matter has been consistently associated with early death and increased morbidity, particularly raising the risk of cardiovascular disease.
C. Macchi, N. Ferri, C. Favero, L. Cantone, L. Vigna, A. Pesatori, M. Lupo, C. Sirtori, A. Corsini, V. Bollati, M. Ruscica   +10 more
semanticscholar   +1 more source

Proprotein convertase subtilisin kexin 9 inhibitors: Current status and future directions

Journal of Clinical and Preventive Cardiology, 2017
The discovery of proprotein convertase subtilisin kexin 9 (PCSK9) has considerably changed the therapeutic options in the field of lipid management. PCSK9 reduces low-density lipoprotein receptor (LDLR) recycling, leading to a decrease of LDL cholesterol
JPS Sawhney, Saurabh Bagga
doaj   +1 more source

Proprotein convertase subtilisin/Kexin type-9 (PCSK-9) inhibitors induced liver injury - a retrospective analysis

Journal of Community Hospital Internal Medicine Perspectives, 2020
Background Proprotein convertase subtilisin/Kexin type 9 (PCSK-9) inhibitors induced liver dysfunction in patients with or without previous liver injury, and this is not well discussed in the previous literature.
Yousuf Zafar, Yasar Sattar, Waqas Ullah, Sohaib Roomi, Mamoon-Ur- Rashid, Muhammad Shayan Khan, Laura Schmidt   +6 more
doaj   +1 more source

Severe obesity and diabetes insipidus in a patient with PCSK1 deficiency. [PDF]

, 2013
Non-synonymous mutations affecting both alleles of PCSK1 (proprotein convertase 1/3) are associated with obesity and impaired prohormone processing. We report a proband who was compound heterozygous for a maternally inherited frameshift mutation and a ...
Bochukova, Elena, Candela, Ninfa, Farooqi, I Sadaf, Fox, Joyce, Frank, Graeme R, Jovanovic, Zorica, Levine, Jeremiah, O'Rahilly, Stephen, Papenhausen, Peter R   +8 more
core   +3 more sources

The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis.

European Heart Journal, 2016
AIMS We performed a network meta-analysis of randomized controlled trials (RCTs) in patients with primary hypercholesterolaemia to compare the impact of proprotein convertase subtilisin-kexin type 9 serine protease (PCSK9) inhibitors with placebo and ...
M. Lipinski, U. Benedetto, R. O. Escárcega, G. Biondi‐Zoccai, T. Lhermusier, Nevin C. Baker, R. Torguson, H. Brewer, R. Waksman   +8 more
semanticscholar   +1 more source